Mantle cell lymphoma (MCL) accounts for 5-10% of all nonHodgkin lymphomas and has the worst prognosis among all lymphomas. The hallmark of MCL is a t(11;14) translocation that results in overexpression of cyclin D1 by tumor cells of virtually all patients. In this study, we examined whether cyclin D1 could be an effective tumor-associated antigen for immunotherapy. We identified cyclin D1 peptides for HLA-A*0201 and generated peptide-specific CD8 þ T-cell lines from HLA-A*0201 þ blood donors and MCL patients. These cell lines proliferated in response to cyclin D1 peptide-pulsed stimulatory cells. Moreover, the T cells efficiently lysed peptide-pulsed but not unpulsed T2 cells and autologous dendritic cells; cyclin D1 
Introduction
Mantle cell lymphoma (MCL) is a well-defined lymphoid neoplasm characterized by a proliferation of a specific population of mature B lymphocytes.
1,2 MCL accounts for 5-10% of all non-Hodgkin lymphomas and is considered an aggressive malignancy. 3 MCL is associated with high relapse rates 4 and has the worst prognosis among lymphomas, with a median survival of approximately 3 years. There have been only a few reported long-term survivors. 5, 6 Although MCL has been treated with chemotherapy, radiotherapy, hematopoietic stem cell transplantation, molecular targeted therapy and combination therapy with the above treatments, no standard treatment approach has been established to date. 5 Therefore, new strategies are needed to improve the overall survival of patients and decrease treatment-associated morbidity.
Adoptive T-cell therapy with antigen-specific T cells is a promising approach for the treatment of cancers. 7 The demonstration of autologous idiotype-specific T cells and evidence of clinical response to allogeneic donor lymphocyte infusions indicate that anti-idiotypic cytotoxic T lymphocytes (CTLs) have been generated against human B-cell idiotypes. [8] [9] [10] Purified autologous immunoglobulin protein has been used as a vaccine for human patients with lymphoma. 11 However, despite the elegant nature of the Id vaccine approach, shortcomings of this strategy include the requirement of producing a custommade protein for each patient and the limitation of the antitumor response to a weak antigen. 12 In addition to optimizing immunotherapy methods, there is an urgent need to search for and utilize novel shared lymphoma antigens to efficiently stimulate anti-lymphoma CTL responses in most treated patients.
Mantle cell lymphoma is genetically characterized by a t(11;14)(q13;q32) translocation that juxtaposes the protooncogene CCND1, which encodes cyclin D1, at chromosome 11q13, to the Ig heavy chain gene at chromosome 14q32. As a consequence of the translocation, cyclin D1 becomes constitutively overexpressed in virtually all patients. 13 This genetic alteration is thought to be the primary event in the pathogenesis of the tumor, 14 probably by facilitating the deregulation of the cell cycle at the G1-S phase transition. 13, 15 However, specific lentiviral short hairpin RNA-mediated knockdown of cyclin D1 in MCL showed minimal effects on cell survival, suggesting the possibility that cyclin D1 overexpression may represent an initiating event in MCL lymphomagenesis. 16 Therefore, the overexpression of cyclin D1 by tumor cells of all MCL patients provides a very attractive antigenic target for immunotherapy aiming at expanding tumor-specific T cells to control MCL growth and proliferation.
On the basis of these observations, we hypothesized that cyclin D1 may be a potent and universally expressed tumorassociated antigen (TAA) for MCL. In this study, we searched for high-affinity cyclin D1 peptides for HLA-A*0201 molecules, and generated and characterized cyclin D1 peptide-specific CTLs obtained from healthy blood donors and lymphoma patients. Our study clearly shows the potential of cyclin D1 as an important antigenic target for anti-lymphoma immunotherapy.
Materials and methods

Tumor cells and patients
Human mantle cell lymphoma lines (HMCLLs) used in these studies include MINO, Granta 519, SP53 and Jeko-1. These cell lines are positive for the t(11;14)(q13; q32) translocation and for HLA-A*0201. Human myeloma cell line ARP-1, which is cyclin D1 þ but HLA-A*0201 À , was used as a control. All cell lines were maintained in RPMI-1640 medium (Life Technologies, Grand Island, NY, USA) supplemented with 10% heatinactivated bovine serum, penicillin (10 000 units/ml; Sigma-Aldrich, St Louis, MO, USA), streptomycin (10 mg/ml; Sigma-Aldrich), gentamicin (50 mg/ml; Sigma-Aldrich) and L-glutamine (29.2 mg/ml; Life Technologies). Blood and tumor samples were obtained from patients with MCL after they gave informed consent. Buffy coat blood of healthy donors was obtained from our institutional blood bank. Mononuclear cells were separated by Ficoll-Hypaque density centrifugation, and MCL cells were isolated by using anti-CD20 magnetic microbeads (Miltenyi Biotec, Auburn, CA, USA). Purity of isolated tumor cells (CD19 þ and CD5 þ and light chain restriction) was confirmed to be greater than 95% by flow cytometric analysis. Aliquots of purified lymphoma cells and peripheral blood mononuclear cells (PBMCs) were cryopreserved in liquid nitrogen until use. The study was approved by the Institutional Review Board at The University of Texas M.D. Anderson Cancer Center.
Generation of dendritic cells
Monocyte-derived mature dendritic cells (DCs) were generated from PBMCs by using the standard protocols. [17] [18] [19] Briefly, PBMCs were allowed to adhere in culture flasks for 2 h, and non-adherent cells were collected and cryopreserved for future use. The adherent cells were cultured in Aim-V medium (Invitrogen Co., Grand Island, NY, USA) supplemented with granulocyte macrophage-colony-stimulating factor (10 ng/ml) and IL-4 (10 ng/ml, both from R&D Systems, Minneapolis, MN, USA), with further addition of cytokines every other day. After 5 days of culture, DCs were induced to maturation by addition of tumor necrosis factor-a (10 ng/ml) and interleukin (IL)-1b (10 ng/ml, both from R&D Systems) for 48 h.
Immunophenotyping and intracellular cytokine staining
Phycoerythrin-or fluorescein isothiocyanate-conjugated monoclonal antibodies (mAbs) were added to cell pellets, incubated for 30 min on ice, and washed three times before analysis. Intracellular cytokine staining was performed by using the Cytofix/Cytoperm kit (BD Pharmingen, San Diego, CA, USA). Samples were analyzed by using a flow cytometer (FACSCaliber; Becton Dickinson, Mountain View, CA, USA).
Immunohistochemistry
For immunohistochemical evaluation, lymph node tissues were stained by using mAb specific for human cyclin D1 (GeneTex Inc., San Antonio, TX, USA). Slides were counterstained with Harris hematoxylin and examined by standard light microscopy. Samples were analyzed by using an Olympus BX51TF microscope equipped with UPlan FL Â 40/0.75 and Â 20/0.50 objective lenses (Olympus, Orangeburg, NY, USA). Pictures were taken by using Olympus QColor3 and analyzed by using QCapture 2.60 software (QImaging).
Western blot analysis
Western blot analysis was used to detect cyclin D1 protein expression in HMCLLs. Cell lysates were subjected to SDSpolyacrylamide gel electrophoresis analysis. After transfer to nitrocellulose membrane and subsequent blocking, the membranes were immunoblotted with mouse anti-human cyclin D1 antibody (Cell Signaling Technology Inc., Beverly. MA, UAS) and visualized with HRP-conjugated donkey anti-goat IgG antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA), followed by enhanced chemiluminescence (Pierce Biotechnology, Rockford, IL, USA) and autoradiography.
Peptide-T2 cell-binding assay
All peptides were synthesized in the Protein Chemistry Core Laboratory at Baylor College of Medicine. The purity of synthetic peptides was confirmed to be greater than 98% by reverse-phase high performance liquid chromatography and mass spectrometry. Synthetic peptides were dissolved in dimethylsulfoxide (Sigma-Aldrich), and stored at 20 1C until use.
Peptides binding to HLA-A*0201 molecules were measured by using the T2 cell line according to a protocol described earlier. 20 Briefly, T2 cells were incubated overnight with 3 mg/ml of b 2 -microglobulin (Sigma-Aldrich) and different concentrations of peptides, followed by washing and incubation with fluorescein isothiocyanate-labeled anti-HLA-A*0201 mAb BB7.2 (BD Pharmingen). After washing, cells were analyzed for the levels of HLA-A*0201 expression by flow cytometry. HLA-A*0201 expression was quantified according to the formula ((mean fluorescence with peptideÀmean fluorescence without peptide)/mean fluorescence without peptide) Â 100%.
Generation of cyclin D1-specific CD8
þ T-cell lines
Cyclin D1-specific T cells were generated from PBMCs of HLA-A*0201 þ blood donors and MCL patients by repeated stimulation of autologous T cells with peptide-loaded mature DCs, as we have reported earlier for other TAAs. 21, 22 Briefly, the non-adherent cells of PBMCs (2 Â 10 6 /ml; used as a T-cell Cyclin D1 as a tumor antigen for MCL M Wang et al population) were cocultured in 50-ml tissue-culture flasks at 37 1C in 5% CO 2 for 7-10 days in Aim-V medium supplemented with 10% pooled human serum (T-cell medium) with mature DCs (2 Â 10 5 /ml) preincubated with cyclin D1 peptides at a final concentration of 20 mg/ml at 37 1C for 2 h. After culture, T cells were collected and restimulated with cyclin D1 peptide-pulsed autologous mature DCs every week, and the cultures were fed every 5 days with fresh medium containing recombinant IL-2 (20 IU/ml), IL-7 (5 ng/ml) and IL-15 (5 ng/ml; all from R&D System). Induction of cyclin D1-specific T cells was monitored weekly by using a T-cell proliferation assay and cyclin D1 peptide-HLA-A*0201 tetramers (synthesized by the MHC Tetramer Laboratory, Baylor College of Medicine, Houston, TX, USA). After 5-6 cycles of in vitro stimulation and selection, T-cell lines were established and expanded in T-cell medium containing IL-2 (100 IU/ml), IL-7 (5 ng/ml) and IL-15 (5 ng/ml) for 2 weeks and subjected to functional tests.
Proliferation assays
T cells (5 Â 10 4 per 100 ml per well) were seeded on 96-well U-bottom tissue culture plates (Corning Incorporated, Corning, NY, USA) in T-cell medium. Varying numbers of autologous mature DCs loaded with or without cyclin D1 peptides were added to the plates and cultured for 4 days at 37 1C in 5% CO 2 . T-cell proliferation was measured after overnight incubation with 3 [H]-thymidine (0.5 mCi per 0.037 MBq per well). Results are expressed as mean count per minute (c.p.m.) of triplicate cultures. In some experiments, cultured T cells were labeled with 5(6)-carboxyfluorescein diacetate succinimidyl ester (5 mM; Molecular Probes, Eugene, OR, USA) for 10 min at 37 1C. After washing, labeled T cells were seeded on 24-well plates and incubated with various numbers of autologous mature DCs loaded with or without cyclin D1 peptides for 5 days. Flow cytometry analysis was used to detect dilutions of carboxyfluorescein diacetate succinimidyl ester. 23 
Cytotoxicity assay
The standard 4-h 51 Cr-release assay 22 was performed to measure cytolytic activity of the T cells against target cells, including autologous DCs or T2 cells loaded with or without peptides, HMCLLs and primary MCL cells isolated from patients. Target cells were incubated with 100 mCi of 51 Cr-sodium chromate for 1 h, washed extensively, seeded (1 Â 10 4 cells per well) on 96-well U-bottom plates in T-cell medium, and cocultured for 4 h with various numbers of T cells. All assays were performed in triplicate. Results are expressed as mean percentages of 51 Cr release calculated as follows: ((sample countsÀspontaneous counts)/(maximum countsÀspontaneous counts)) Â 100%. Spontaneous release was less than 20% of the maximum 51 Cr uptake.
To determine whether the cytolytic activity was restricted by major histocompatibility complex (MHC) class I or II molecules, 20 mg/ml mAbs against HLA-ABC (W6/32) or HLA-A*0201 (BB7.2; both from Serotec Ltd, Oxford, UK), HLA-DR (B8.12.2; Immunotech, Marseilles, France) or isotypic controls (Immunotech) were added to the cultures at the start of the assay. Cyclin
ELISPOT assay
Detailed methods of the ELISPOT assay for enumeration of antigen-specific, interferon (IFN)-g-secreting cells have been described earlier. 24, 25 The number of IFN-g spots was enumerated by an automate ImmunoSpot analyzer (Cellular Technology Ltd, Cleveland, OH, UAS). All samples were run in duplicate. Data are expressed as the mean number of IFN-gsecreting cells/10 4 T cells.
Statistical analysis
The Student's t-test was used to compare various experimental groups. A P-value less than 0.05 was considered statistically significant. Unless otherwise indicated, means and s.d. are shown.
Results
Cyclin D1 is overexpressed in MCL but not in normal B cells
Immunohistochemistry and western blot analyses were used to examine the expression of cyclin D1 in primary MCL in lymph node samples of patients and in established HMCLLs, respectively. As shown in Figure 1a , cyclin D1 protein was only detected in lymphoma cells with a typical mantle zone pattern but not in normal B cells located in the germinal center and interfollicular area. Cyclin D1 protein was also detected in all four HMCLLs (Figure 1b) . These results confirm the universal expression of cyclin D1 in MCL cells.
Selection of cyclin D1 peptides
The sequence of human cyclin D1 was reviewed for peptides that could potentially bind to HLA-A*0201 by using a peptide binding database (http://www.bimas.dcrt.nih.gov), and several peptide sequences were obtained. After comparing the predictive binding scores, we identified and selected two peptides that could potentially bind HLA-A*0201 molecules (P101 and P22). Heteroclitic peptides, by replacing position-1 amino acid with tyrosine and/or C-terminal amino acid with valine, 26, 27 were made (P101 to Py101, and P22 to P22v and Py22v), which had significantly higher predictive binding scores than the original ones (Table 1) . A peptide-T2-binding assay confirmed that heterolitic peptides have higher binding affinity ( Figure 2a ) and binding stability (Figure 2b ). Dickkopf-1 (DKK1) peptide P66 and its heterolitic peptide P66v 21 were used as controls in binding affinity studies presented in Figure 2a .
Generation of cyclin D1 peptide-specific CD8 þ T-cell lines
As the solubility of the Py101 peptide was better than that of P22 heterolitic peptides, we chose to use the Py101 cyclin D1 peptide as an immunogen to propagate cyclin D1-specific T cells in this study. To generate cyclin D1 peptide-specific T cells from HLA-A*0201 þ blood donors and MCL patients, autologous mature DCs pulsed with the Py101 peptide were used as antigenpresenting cells. After 5-7 rounds of in vitro stimulation, T-cell lines were obtained, which contained about 45% CD4 þ and 55% CD8 þ T cells. As exemplified by the results of peptide-tetramer staining, the frequencies of peptide-specific CD8 þ T cells increased during in vitro stimulation; from 5.7% of specific T cells at fourth stimulation to 19.7% at sixth stimulation (Figure 3a) . The Cytolytic activity of cyclin D1-specific CD8 þ T cells
The standard 51
Cr-release assay was used to examine the cytotoxicity of the T cells against different target cells. First, our results show that the T cells specifically lysed autologous DCs pulsed, but not unpulsed, with the cyclin D1 peptide Py101 (Figure 4a) . Next, we assessed the cytotoxic activity of the T cells against T2 cells pulsed with cyclin D1 and control peptides, and showed that these T cells specifically lysed T2 cells pulsed with cyclin D1 Py101 (Po0.01, compared with control peptides) but not unpulsed T2 cells or T2 cells pulsed with irrelevant peptides, which included HIV type 1 reverse transcriptase (HIV-pol), 28 influenza virus matrix protein (Flu-matrix) 29 and cyclin D1 P22v (Figure 4b ). These results further confirm the specificity of the T cells.
We proceeded to examine the cytolytic activity of the T cells against lymphoma cells, including HMCLLs and primary lymphoma cells from MCL patients. As shown in Figure 4c (Figure 4d ). We also examined whether the T cells were cytolytic to normal hematopoietic cells. In these experiments, autologous mature DCs, blood B cells (purified by using anti-CD19 antibody-coated magnetic microbeads) and PBMCs were used as target cells. As shown in Figure 4d , the T cells did not kill HLA-A*0201 þ DCs, B cells or PBMCs. Together, these results show that the T cells are not only able to lyse cyclin D1 peptide-pulsed DCs and T2 cells, but also lymphoma cells, which included primary lymphoma cells from HLA-A*0201 þ MCL patients. These findings indicate that the T cells are potent and cyclin D1-specific CTLs, and that the cyclin D1 peptide is naturally presented in the context of HLA-A*0201 molecules by lymphoma cells and shared among patients.
MHC restriction and cytolytic pathways of the T cells
To determine MHC restriction of the T-cell-mediated cytotoxicity, we examined the inhibitory effects of anti-MHC mAbs. As shown in Figure 5a , mAbs against HLA-ABC or HLA-A*0201 significantly (70-80%) inhibited T-cell-mediated cytotoxicity against lymphoma cells (Po0.01, compared with medium control). No inhibitory effect was observed with mAb against HLA-DR or isotype control IgG. The results indicate that the cytotoxicity is attributed to MHC class I, and more specifically, HLA-A* 0201-restricted CD8 þ T cells. 
Cyclin D1 as a tumor antigen for MCL M Wang et al
Flow cytometry analysis was used to examine the expression of granzyme B, granzyme A, perforin and Fas ligand by the T cells. These results indicate that the CTLs may kill their target cells through the perforin-granzyme pathways, because they expressed perforin and high levels of granzyme B and granzyme A but not Fas ligand (Figure 5b) . The T cells also expressed CD45RO, indicating that they were memory effector cells. [30] [31] [32] Expression and production of IFN-g by the T cells Preclinical 36-39 and clinical Phase I studies [40] [41] [42] [43] using these TAAs have generated promising results, with minimal toxicity and potential efficacy. Cyclin D1 may belong to this category of TAAs. Owing to a chromosomal t(11;14)(q13;q32) translocation, overexpression of cyclin D1 is present in the lymphoma cells of almost 100% of patients with MCL, whereas the expression of cyclin D1 in normal cells is low and transient. 14, 44, 45 Our own study has confirmed the expression of cyclin D1 in all MCL samples that we examined. Furthermore, cyclin D1 expression and activity is crucial for MCL growth, as it is a well-known cell cycle regulator and promotes G1-to S-phase cell cycle progression. 46 Hence, MCL cells cannot cease to express or downregulate the expression of cyclin D1 to escape immune attack.
The aim of this study was to examine whether cyclin D1 is a suitable TAA for immunotherapy in MCL. To generate cyclin D1-specific CTLs, we identified and synthesized the top two candidate cyclin D1 peptides P101 and P22 after searching cyclin D1 sequence for HLA-A*0201-binding motifs. To enhance their binding affinity, heteroclitic peptides 26, 27 for P101 (Py101) and P22 (P22v and Py22v) were synthesized. All of the heteroclitic peptides had increased binding affinity compared with the original peptides ( Table 1) . In this study, we used Py101 as cyclin D1 antigen to generate cyclin D1-specific CTLs. From HLA-A*0201 þ healthy donors and MCL patients, several cyclin D1 Py101-specific T-cell lines were obtained. These T cells proliferated in response to, and were cytolytic against, Py101-pulsed T2 and autologous DCs, but not to the unpulsed cells. Also, these T cells efficiently lysed cyclin D1 þ /HLA-A*0201 þ HMCLLs MINO, SP53, Jeko-1 and Granta 519, and more importantly, primary lymphoma cells from HLA-A*0201 þ MCL patients. As expected, these CTLs did not kill normal autologous blood cells, including DCs, B cells and PBMCs, or primary lymphoma cells from HLA-A*0201 À MCL patients. These findings indicate that the T cells are potent CTLs that recognize cyclin D1 peptides naturally processed and presented by lymphoma but not normal blood cells in the context of surface MHC class I (HLA-A*0201) molecules. Our study also suggests that cyclin D1-specific CTLs may be promising effector cells for immunotherapy of MCL.
As we started with CD3 þ T cells in generating cyclin D1 Py101-specific CTLs, our cell lines contained both CD4 þ and CD8 þ T cells. However, it is evident that CD8 þ T cells in the cell lines were cyclin D1-specific T cells because the cytolytic activity of the T cells was blocked by mAbs against HLA-ABC and HLA-A*0201, but not by mAb against MHC class II molecules. By using different immune assays, we characterized the T cells. Phenotypically, the gated CD8 þ T cells expressed CD45RO, perforin and granzymes B and A, but not Fas ligand, indicating that they were memory effector CTLs that may mediate their cytolytic activity through the granzyme-perforin pathways. Functionally, the T cells secreted IFN-g but not IL-4, and showed strong cytotoxic activity against their target cells, indicating that they are type-1 CTLs. 32, 33 CD8 þ CTLs constitute one of the most important arms of the immune system, with the capacity to recognize and destroy cancerous cells. 47 Thus, these CTLs could be used to eliminate residual MCL cells remaining after initial frontline therapies such as rituximab and/or combination chemotherapy regimens. 48, 49 In conclusion, our study shows that cyclin D1 peptidespecific CTLs can be generated from both healthy blood donors and MCL patients by stimulating autologous T cells with DCs pulsed with cyclin D1 peptides. These CTLs may be promising effector cells for immunotherapy in MCL because they are potent killer cells that are able to specifically and effectively lyse autologous primary lymphoma cells from MCL patients but not normal blood cells in vitro. This study provides preliminary evidence to support our hypothesis that cyclin D1 may be used as universal vaccines to immunize patients with MCL. Thus, our study lays a foundation for additional preclinical and clinical studies to evaluate the safety, feasibility and efficacy of cyclin D1-based immunotherapy in the treatment of the patients. 
